Submissions received by the Committee

Inquiry into Consumer Access to Pharmaceutical Benefits

Submissions received by the Committee

Sub No. Submitter  
1 Confidential Submission  
2 Thornley, Dr Stephen

(PDF 32KB)

3 Confidential Submission  
4 Confidential Submission  
5 Kandiah, Dr David A (PDF 4KB)
6 Eisman, Professor John (PDF 40KB)
7 Littlejohn, Professor Geoff (PDF 32KB)
8 Glendenning, Professor Paul (PDF 4KB)
9 Australian and NZ Bone and Mineral Society (PDF 889KB)
10 Oakley, Dr Stephen (PDF 13KB)
11 Major, Dr Gabor (PDF 1209KB)
12 Australian Medical Association (AMA) (PDF 66KB)
13 Inderjeeth, Dr Charles A. (PDF 8KB)
14 Chronic Illness Alliance (PDF 84KB)
15 Joint Epilepsy Council of Australia and Epilepsy Australia (PDF 74KB)
16 Generic Medicines Industry Association Pty Ltd (PDF 854KB)
17 Pharmaceutical Society of Australia (PDF 272KB)
18 The Pharmacy Guild of Australia

(PDF 366KB)

19 Janssen-Cilag Australia (PDF 603KB)
20 Consumers Health Forum of Australia (PDF 336KB)
21 Osteoporosis Australia (PDF 28KB)
22

Paroxysmal Nocturnal Haemoglobinuria (PNH) Support Association of Australia

(PDF 7323KB)
22a Attachment to submission 22 (PDF 212KB)
23 Sanofi-Aventis Australia Pty Limited (PDF 59KB)
24 Arthritis Australia (PDF 298KB)
25 Mental Health Council of Australia (PDF 57KB)
26 Carers Australia (PDF 36KB)
27 Department of Health and Ageing (PDF 166KB)
28 MS Australia

(PDF 260KB)

29 Medicines Australia cover letter and Submission (PDF 60KB) (PDF 242KB)
30 Hill, Minister John (PDF 204KB)
31 AstraZeneca Pty Ltd (PDF 9329KB)
32 Faunce, Dr Thomas (PDF 359KB)
33 Pfizer Australia (PDF 482KB)
34 Australian NPC Disease Foundation Inc (VIC) (PDF 531KB)

 

No. Answers to Questions on Notice
1
 
Australian and NZ Bone and Mineral Society (Submission no.9)
Response to questions taken on notice at public hearing 07.05.10, received 22.05.10
(PDF 58KB)
2
 
Chronic Illness Alliance (Submission no.14)
Response to questions taken on notice at public hearing 07.05.10
(PDF 23KB)
3
 
Generic Medicines Industry Association Pty Ltd (Submission no.16)
Additional information arising from the hearing, dated 18.05.10
(PDF 236KB)
4

 
The Pharmacy Guild of Australia (Submission no.18)
Supplementary submission including response to questions taken on notice at public hearing 07.05.10, received 14.05.10
(PDF 218KB)
5
 
Janssen-Cilag Australia (Submission no.19)
Supplementary submission received 31.05.10
(PDF 3005KB)
6
 
Consumers Health Forum of Australia (Submission no.20)
Response to questions taken on notice at public hearing 07.05.10, received 19.05.10
(PDF 1205KB)
7
 
Sanofi-Aventis Australia Pty Limited (Submission no.23)
Response to questions taken on notice at public hearing 07.05.10, received 31.05.10
(PDF 694KB)
8
 
Arthritis Australia (Submission no.24)
Response to questions taken on notice at public hearing 07.05.10, received 20.05.10
(PDF 1135KB)
9
 
Mental Health Council of Australia (Submission no.25)
Response to questions taken on notice at public hearing 07.05.10, received 25.05.10
(PDF 72KB)
10
 
Department of Health and Ageing (Submission no.27)
Response to answers taken on notice at public hearing 07.05.10, received 15.06.10
(PDF 1269KB)
11

 
Medicines Australia (Submission no.29)
Supplementary submission and response to questions taken on notice at public hearing 07.05.10, received 31.05.10
(PDF 78KB)
12

 
AstraZeneca Pty Ltd (Submission no.31)
Response to questions taken on notice at public hearing 07.05.10 and Supplementary submission, received 31.05.10
(PDF 1117KB)
13
 
Pfizer Australia (Submission no.33)
Supplementary submission received 01.06.10
(PDF 137KB)
14
 
Pharmaceutical Benefits Advisory Council
Response to questions taken on notice at public hearing 07.05.10, received 16.06.10
(PDF 6248KB)

 

No.
 
Responses to the Memorandum of Understanding signed between the Australian Government and Medicines Australia
1 The Pharmacy Guild of Australia, received 09.06.10 (PDF 75KB)
2 Medicines Australia, received 10.06.10 (PDF 1328KB)
3 Department of Health and Ageing, received 16.06.10 (PDF 58KB)
4 Generic Medicines Industry Association Pty Ltd, received 17.06.10 (PDF 448KB)

 

No. Additional Information received
1
 
Australian and NZ Bone and Mineral Society
Additional information referred to and provided at  public hearing 07.05.10
(PDF 1243KB)
 
2
 
Generic Medicines Industry Association Pty Ltd
Correction to the record from public hearing 07.05.10, dated 17.05.10
(PDF 199KB)
 

For further information, contact:

Committee Secretary
Senate Standing Committees on Community Affairs
PO Box 6100
Parliament House
Canberra ACT 2600
Australia

Phone: +61 2 6277 3515
Fax: +61 2 6277 5829
Email: community.affairs.sen@aph.gov.au